UDENYCA® (pegfilgrastim-cbqv) A Safe, Effective, and Affordable Alternative to Neulasta® (pegfilgrastim)

September 3, 2020

Biosimilars are as safe, effective, and affordable alternatives to reference biologics that meet rigorous standards set by the US Food and Drug Administration. Join us to learn more about biosimilars and UDENYCA® (pegfilgrastim-cbqv), a pegfilgrastim biosimilar.  The presentation, scheduled for September 8, 2020 from 3:00 – 3:45 PM EST, will include information on the mechanism of action, efficacy, safety, indication, and dosing of UDENYCA®, along with an overview of patient support services offered through Coherus COMPLETETM.